Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma
Clinicians need to be aware of the range of factors involved in managing the treatment and supportive care of patients with multiple myeloma.  It is important for clinicians to discuss practical patient examples and the rationale for the various treatment choices based on expert experience and recent data from trials to aid the decision-making process for clinicians treating patients with myeloma.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma

Management of Multiple Myeloma

Clinical Updates: Primary Therapy of Multiple Myeloma
It is important to help clinicians to keep up-to-date with the newer treatment options available to help select the most efficient treatment strategy. In addition, knowledge of the relevant side effects of the novel drugs reported in pivotal clinical studies and strategies for their prevention and management is also equally important to improve overall patient outcomes.
Keynote Session: Patient Experience with Innovative Therapies

The development of new and innovative cancer treatments has expanded the options available to manage patients with cancer.  However, with these advances come challenges for healthcare providers and patients.

CAR T-Cell Therapy: Recent Advances and Future Considerations
NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This webinar describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.
Emerging Options and Sequencing Therapies for Relapsed Multiple Myeloma

Promising clinical responses have even been seen in heavily pretreated patients, suggesting that the new therapeutic options benefit those who have exhausted all traditional lines of therapy.

Current Approaches to Initial Treatment of Newly Diagnosed Multiple Myeloma

The number of treatment options for both transplant eligible and transplant ineligible patients continues to grow year after year.  Regimens previously approved in the second-line setting are proving to be efficacious as primary therapy.

Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms

Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.

CAR T-Cell Therapy: Recent Advances and Future Considerations

Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options.

NCCN Guidelines® Updates: Management of Multiple Myeloma

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.

Pages

Subscribe to RSS - Multiple Myeloma